UBS Group AG reduced its position in Geron Corporation (NASDAQ:GERN) by 57.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,021 shares of the biopharmaceutical company’s stock after selling 70,992 shares during the period. UBS Group AG’s holdings in Geron Corporation were worth $118,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in GERN. Raymond James Financial Services Advisors Inc. raised its position in shares of Geron Corporation by 31.0% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 57,056 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 13,500 shares in the last quarter. American International Group Inc. raised its position in shares of Geron Corporation by 7.1% in the first quarter. American International Group Inc. now owns 92,964 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 6,140 shares in the last quarter. Creative Planning raised its position in shares of Geron Corporation by 17.9% in the first quarter. Creative Planning now owns 101,868 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 15,500 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Geron Corporation by 0.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 112,793 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 732 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Geron Corporation by 91.9% in the first quarter. UBS Asset Management Americas Inc. now owns 105,125 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 50,334 shares in the last quarter. Institutional investors and hedge funds own 38.16% of the company’s stock.

Shares of Geron Corporation (NASDAQ:GERN) traded down 0.48% during trading on Friday, hitting $2.08. The stock had a trading volume of 1,094,927 shares. The stock’s market cap is $331.16 million. Geron Corporation has a 12 month low of $1.81 and a 12 month high of $3.15. The company’s 50 day moving average price is $2.68 and its 200 day moving average price is $2.47.

Geron Corporation (NASDAQ:GERN) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Geron Corporation had a negative return on equity of 21.30% and a negative net margin of 433.72%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.38 million. During the same quarter in the prior year, the company earned ($0.05) EPS. Geron Corporation’s revenue was down 19.0% on a year-over-year basis. Equities research analysts expect that Geron Corporation will post ($0.18) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/13/geron-corporation-nasdaqgern-stake-cut-by-ubs-group-ag.html.

GERN has been the topic of several research reports. Zacks Investment Research upgraded Geron Corporation from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Thursday, June 15th. BidaskClub lowered Geron Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, FBR & Co restated a “buy” rating on shares of Geron Corporation in a research note on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $3.88.

About Geron Corporation

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Corporation (NASDAQ:GERN).

Institutional Ownership by Quarter for Geron Corporation (NASDAQ:GERN)

Receive News & Ratings for Geron Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corporation and related companies with MarketBeat.com's FREE daily email newsletter.